HRS-9821 Powder for Inhalation
Phase 1
Guangdong Hengrui Pharmaceutical Co., LtdHRS-9821 Powder for Inhalation is one of 13 therapeutic programs targeting COPD. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
17 competitors in COPD
#DrugCompanyPhaseTrials
1Spiriva
Boehringer IngelheimApproved
Daliresp
AstraZenecaApproved
Striverdi Respimat
Boehringer IngelheimApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Marinol
Jazz PharmaceuticalsPhase 3
Medrol
PfizerPreclinical
Dexpramipexole Dihydrochloride
AAreteia Therapeutics
Phase 2
DUPIXENT
RegeneronPreclinical
Xopenex Hfa
HHikma Pharmaceuticals LLC
Preclinical
HRS-9821 Powder for Inhalation
Guangdong Hengrui Pharmaceutical Co., LtdPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]